EyePoint Announces Pricing of Public Offering

WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offering price of $12.00 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 1,500,000 shares of its common stock at a price to the public of $11.999 per each pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds from this offering are expected to be approximately $150 million, before deducting underwriting discounts and commissions and other offering expenses payable by EyePoint. All of the shares of common stock and pre-funded warrants are being sold by EyePoint. The closing of the offering is expected to occur on or about October 16, 2025, subject to the satisfaction of customary closing conditions. In addition, EyePoint has granted the underwriters an option for a period of 30 days to purchase up to an additional 1,875,000 shares of EyePoint’s common stock at the public offering price, less underwriting discounts and commissions.

J.P. Morgan, Jefferies, Citigroup, and Guggenheim Securities are acting as joint book running managers for the offering.

EyePoint intends to use the net proceeds that it will receive from the offering to advance clinical development of DURAVYU for wet age related macular degeneration (wet AMD) and diabetic macular edema (DME), as well as support its earlier stage pipeline development initiatives, and for general corporate purposes.

The securities described above are being offered by the Company pursuant to an automatically effective shelf registration statement on Form S-3ASR (No. 333-290867) previously filed with the Securities and Exchange Commission (SEC) on October 14, 2025.

The securities are being offered by means of a prospectus supplement and accompanying prospectus relating to the offering that form a part of the registration statement. A preliminary prospectus supplement relating to the offering was filed with the SEC on October 14, 2025 and is available on the SEC’s website at www.sec.gov. The final prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and also will be available on the SEC’s website at www.sec.gov. Before investing in the offering, you should read each of the prospectus supplement and the accompanying prospectus relating to the offering in their entirety as well as the other documents that EyePoint has filed with the SEC that are incorporated by reference in the prospectus supplement and the accompanying prospectus relating to the offering, which provide more information about EyePoint and the offering. Copies of the final prospectus supplement, when available, and accompanying prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at [phone], or by email at [e-mail]; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, or by telephone at [phone], or by email at [e-mail]; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at [phone]; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at [phone], or by email at [e-mail].